Zacks Investment Research upgraded shares of Caladrius Biosciences (NASDAQ:CLBS) from a hold rating to a buy rating in a research report sent to investors on Monday. They currently have $5.50 price objective on the biotechnology company’s stock.

According to Zacks, “Caladrius Biosciences, Inc. is an immunotherapy company which specializes in cell process optimization, development and manufacturing. Its product candidate consists of NBS20, a targeted cancer immunotherapy product for the treatment of metastatic melanoma; NBS10, an ischemic repair product to preserve heart muscle function following an acute myocardial infarction and NBS03D, an immune modulation product for the treatment of diabetes which are in different clinical trials. Caladrius Biosciences, Inc., formerly known as NeoStem, Inc., is headquartered in New York. “

Other equities research analysts have also issued reports about the company. HC Wainwright lifted their target price on Caladrius Biosciences to $15.00 and gave the company a buy rating in a research report on Monday, September 10th. Chardan Capital reaffirmed a buy rating on shares of Caladrius Biosciences in a research report on Wednesday, August 29th.

Shares of NASDAQ CLBS opened at $4.53 on Monday. The firm has a market cap of $47.44 million, a price-to-earnings ratio of -2.54 and a beta of 1.22. Caladrius Biosciences has a twelve month low of $3.04 and a twelve month high of $11.65.

Caladrius Biosciences (NASDAQ:CLBS) last issued its earnings results on Thursday, November 8th. The biotechnology company reported ($0.36) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.56) by $0.20. On average, equities research analysts predict that Caladrius Biosciences will post -1.92 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Renaissance Technologies LLC raised its position in Caladrius Biosciences by 42.9% during the 3rd quarter. Renaissance Technologies LLC now owns 280,864 shares of the biotechnology company’s stock valued at $1,657,000 after purchasing an additional 84,301 shares in the last quarter. Dimensional Fund Advisors LP purchased a new position in shares of Caladrius Biosciences in the 1st quarter valued at $197,000. Finally, JPMorgan Chase & Co. purchased a new position in shares of Caladrius Biosciences in the 1st quarter valued at $110,000. 7.64% of the stock is owned by institutional investors and hedge funds.

About Caladrius Biosciences

Caladrius Biosciences, Inc operates as a global healthcare company, which engages in developing cellular therapies that repair damaged tissue, cells and organs and restore their normal function. It is pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease.

Further Reading: Cash Flow Analysis in Stock Selection

Get a free copy of the Zacks research report on Caladrius Biosciences (CLBS)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with's FREE daily email newsletter.